Roche Molecular Systems, Inc. Release: Blood Screening Test That Offers Immediate Viral Discrimination for Three Major Viruses Receives CE Mark

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the cobas® TaqScreen MPX Test, version 2.0 for use on the cobas s 201 system is now commercially available in Europe.

This latest version of the widely used cobas® TaqScreen MPX Test provides increased sensitivity and is the only commercially available test that provides simultaneous viral target resolution on an automated system, removing the need for further time-consuming testing of positive units.